AbbVie Inc. · ABBV · Next earnings

AbbVie Inc. reports Friday, Oct 30, 2026

ABBV reports before market open with consensus EPS at $3.86 and revenue at $17.31B. Last quarter: AbbVie Beats Q1 Estimates on Skyrizi-Rinvoq Strength, Raises Full-Year EPS Guidance

Reports Before market open40 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $3.86 Calendar consensus
Consensus revenue $17.31B Calendar consensus
Report date Oct 30, 2026 Friday, date estimated
Session Before market open 40 days away

Where ABBV left off: FY2026 Q1

Full report

AbbVie Beats Q1 Estimates on Skyrizi-Rinvoq Strength, Raises Full-Year EPS Guidance

EPS surprise +2.3% Reported $2.65 vs $2.59
Revenue surprise +1.9% Reported $15.00B vs $14.72B
Stock move +3.1% Event window
Subsequent drift +7.2% Up to 20 sessions

Full-year adjusted EPS guidance was raised to $14.08-$14.28. Management's guidance sentiment was characterized as raised, and the capex outlook is increasing, reflecting the $1.4B North Carolina and $380M North Chicago manufacturing investments. Specific prior guidance levels were not available in the supplied transcript analysis for a precise before-after comparison.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Biosimilar competition to Humira continues, with potential future biosimilars for Skyrizi.
  • Pricing pressure and low-single-digit erosion expectations for the immunology portfolio.
  • Regulatory uncertainty across multiple pipeline submissions, including Rinvoq for alopecia areata, Skyrizi subcutaneous induction, and ABBV-295.
  • Acquired IP R&D expense is impacting operating margins.
  • Macroeconomic headwinds may affect aesthetics demand amid consumer-spending pressure.

Questions analysts left open

  • Impact of upcoming oral psoriasis competitors and biosimilars on Skyrizi market share.
  • Timing and pricing of Skyrizi label extensions and potential pricing erosion.
  • Regulatory timelines for ABBV-295 (obesity), PD-1/VEGF bispecifics, and subcutaneous induction for Crohn's disease.
  • Scope and valuation of recent M&A activity, including the Remagen, Nimble, and Capstan acquisitions.
  • Sustainability of aesthetic growth amid consumer-spending pressure.

Ask FN2 about ABBV next report

Transcript, numbers and history already loaded
What should I watch for in ABBV's next earnings report?How did ABBV guide last quarter, and is consensus above or below that?Give me the bull and bear case going into ABBV earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the ABBV recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent ABBV quarters

All ABBV earnings
+3.1%FY2026 Q1

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q1

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.